Melanie L Rose, Benjamin V M Bajaj, Rachel Jimenez, Sara Dennehy, Keith Allison, Laura Wiltsie, David Ebb, Shannon M MacDonald, Nancy J Tarbell, Torunn I Yock
{"title":"Quality of life in pediatric patients treated with adjuvant proton radiation for craniopharyngiomas.","authors":"Melanie L Rose, Benjamin V M Bajaj, Rachel Jimenez, Sara Dennehy, Keith Allison, Laura Wiltsie, David Ebb, Shannon M MacDonald, Nancy J Tarbell, Torunn I Yock","doi":"10.1007/s11060-025-05112-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pediatric craniopharyngiomas are curable tumors. Significant morbidity is reported from the tumor itself as well as treatments (surgery and radiotherapy (RT)), which adversely affects health-related quality of life (HRQoL) outcomes, which we reported and correlated with other health outcomes.</p><p><strong>Methods: </strong>HRQoL data was collected from a prospective cohort of proton treated patients with craniopharyngiomas (≤ 22 years at the time of RT). Parents and children were surveyed using the Pediatric Quality of Life Inventory (PedsQL) collected at baseline and annually thereafter. We compared last follow-up parent-proxy reports (PPR) and Child-self reports (CSR) in patients with and without treatment sequelae. We compared last follow-up PPR total core scores (TCS) to values representative of a normal population.</p><p><strong>Results: </strong>47 participants were included and median follow-up was 11.2 years. Median age at RT was 9.7 years. PPR and CSR TCS at last follow-up, 70.8 and 75.5 respectively, were significantly lower than normal controls (p < 0.01). At last follow up, PPR TCS was lower in patients with arginine vasopressin deficiency (AVP-D) (65.6 vs. 79.0, p = 0.01), sex hormone deficiency (67.6 vs. 78.85 p = 0.03), and hyperphagia (64.1 vs. 79.4, p < 0.01). Patients who were treated with RT at time of recurrence had 1.40 × (95% CI, 1.08-1.81, p = 0.011) the rate of sequala development compared to those treated at initial diagnosis.</p><p><strong>Conclusions: </strong>HRQoL TCSs were significantly worse than healthy controls. Hyperphagia, AVP-D and sex hormone deficiencies, correlated with worse PPR TCS. Those treated with RT at time of recurrence had higher sequalae burden than those treated at initial diagnosis.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-025-05112-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Pediatric craniopharyngiomas are curable tumors. Significant morbidity is reported from the tumor itself as well as treatments (surgery and radiotherapy (RT)), which adversely affects health-related quality of life (HRQoL) outcomes, which we reported and correlated with other health outcomes.
Methods: HRQoL data was collected from a prospective cohort of proton treated patients with craniopharyngiomas (≤ 22 years at the time of RT). Parents and children were surveyed using the Pediatric Quality of Life Inventory (PedsQL) collected at baseline and annually thereafter. We compared last follow-up parent-proxy reports (PPR) and Child-self reports (CSR) in patients with and without treatment sequelae. We compared last follow-up PPR total core scores (TCS) to values representative of a normal population.
Results: 47 participants were included and median follow-up was 11.2 years. Median age at RT was 9.7 years. PPR and CSR TCS at last follow-up, 70.8 and 75.5 respectively, were significantly lower than normal controls (p < 0.01). At last follow up, PPR TCS was lower in patients with arginine vasopressin deficiency (AVP-D) (65.6 vs. 79.0, p = 0.01), sex hormone deficiency (67.6 vs. 78.85 p = 0.03), and hyperphagia (64.1 vs. 79.4, p < 0.01). Patients who were treated with RT at time of recurrence had 1.40 × (95% CI, 1.08-1.81, p = 0.011) the rate of sequala development compared to those treated at initial diagnosis.
Conclusions: HRQoL TCSs were significantly worse than healthy controls. Hyperphagia, AVP-D and sex hormone deficiencies, correlated with worse PPR TCS. Those treated with RT at time of recurrence had higher sequalae burden than those treated at initial diagnosis.
期刊介绍:
The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.